Literature DB >> 15540242

Agenesis and microdontia of permanent teeth as late adverse effects after stem cell transplantation in young children.

Päivi Hölttä1, Satu Alaluusua, Ulla M Saarinen-Pihkala, Jaakko Peltola, Liisa Hovi.   

Abstract

BACKGROUND: The objective of the current study was to examine the occurrence of tooth agenesis and microdontia in pediatric stem cell transplantation (SCT) recipients.
METHODS: The impact of total body irradiation (TBI) and age at SCT on agenesis and microdontia of permanent teeth was examined in 55 patients from panoramic radiographs. Assessment A1 (for tooth agenesis and microdontia) excluded the third molars, and assessment A2 (for tooth agenesis) included the third molars. Patients were grouped according to TBI status (the TBI group vs. the non-TBI group) and age at SCT (patients age < or = 3.0 years [Group Y], patients ages 3.1-5.0 years [Group M], and patients age > or = 5.1 years [Group O]).
RESULTS: From 1 to 12 teeth were missing in 77%, 40%, and 0% of patients (assessment A1) in Groups Y, M, and O, respectively (Group Y vs. Group M, P=0.055; Group Y vs. Group O, P < 0.001; and Group M vs. Group O, P=0.002), increasing to 83%, 78%, and 43%, respectively, when the third molars were included (assessment A2; P values were not significant). Correspondingly, 75%, 60%, and 13%, respectively, of patients had 1-12 microdontic teeth (assessment A1: Group Y vs. Group M, P=0.306; Group Y vs. Group O, P <0.001; and Group M vs. Group O, P=0.003). Recipient age at the time of SCT was found to have a negative correlation with the number of missing teeth (P=0.001) and microdontic teeth (P=0.005). TBI appeared to have little effect on the prevalence of tooth agenesis (assessment A1: TBI group, 32%; non-TBI group, 29%; assessment A2: TBI group, 72%; non-TBI group, 46%; P values were not significant) or on the prevalence of microdontia (assessment A1: TBI, 41%; non-TBI, 50%; P value was not significant). A tendency toward an increased number of affected teeth was noticed in the group of patients who received TBI.
CONCLUSIONS: Depending on their age at SCT, 50-100% of pediatric SCT recipients will later present with agenesis and/or microdontia of permanent teeth that may jeopardize occlusal development. Young age (< or = 5.0 years) at SCT was found to be a stronger risk factor than TBI, although TBI caused additive impairment.

Entities:  

Mesh:

Year:  2005        PMID: 15540242     DOI: 10.1002/cncr.20762

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Dental abnormalities after chemotherapy in long-term survivors of childhood acute lymphoblastic leukemia 7-40 years after diagnosis.

Authors:  Petter Wilberg; Adriani Kanellopoulos; Ellen Ruud; Marianne Jensen Hjermstad; Sophie Dorothea Fosså; Bente Brokstad Herlofson
Journal:  Support Care Cancer       Date:  2015-09-12       Impact factor: 3.603

2.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Authors:  N S Majhail; J D Rizzo; S J Lee; M Aljurf; Y Atsuta; C Bonfim; L J Burns; N Chaudhri; S Davies; S Okamoto; A Seber; G Socie; J Szer; M T Van Lint; J R Wingard; A Tichelli
Journal:  Hematol Oncol Stem Cell Ther       Date:  2012

Review 3.  A systematic review of dental late effects in survivors of childhood cancer.

Authors:  Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Louis S Constine; Leslie L Robison; Kirsten K Ness
Journal:  Pediatr Blood Cancer       Date:  2013-11-01       Impact factor: 3.167

4.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Authors:  N S Majhail; J D Rizzo; S J Lee; M Aljurf; Y Atsuta; C Bonfim; L J Burns; N Chaudhri; S Davies; S Okamoto; A Seber; G Socie; J Szer; M T Van Lint; J R Wingard; A Tichelli
Journal:  Bone Marrow Transplant       Date:  2012-03       Impact factor: 5.483

Review 5.  Oral and dental late effects in survivors of childhood cancer: a Children's Oncology Group report.

Authors:  Karen E Effinger; Cesar A Migliorati; Melissa M Hudson; Kevin P McMullen; Sue C Kaste; Kathy Ruble; Gregory M T Guilcher; Ami J Shah; Sharon M Castellino
Journal:  Support Care Cancer       Date:  2014-04-30       Impact factor: 3.603

6.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Authors:  Navneet S Majhail; J Douglas Rizzo; Stephanie J Lee; Mahmoud Aljurf; Yoshiko Atsuta; Carmem Bonfim; Linda J Burns; Naeem Chaudhri; Stella Davies; Shinichiro Okamoto; Adriana Seber; Gerard Socie; Jeff Szer; Maria Teresa Van Lint; John R Wingard; Andre Tichelli
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-13       Impact factor: 5.742

7.  The prevalence of dental developmental anomalies among childhood cancer survivors according to types of anticancer treatment.

Authors:  Elinor Halperson; Vered Matalon; Gal Goldstein; Shirly Saieg Spilberg; Karin Herzog; Avia Fux-Noy; Aviv Shmueli; Diana Ram; Moti Moskovitz
Journal:  Sci Rep       Date:  2022-03-16       Impact factor: 4.379

8.  Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma.

Authors:  Wendy L Hobbie; Thomas Moshang; Claire A Carlson; Elizabeth Goldmuntz; Nancy Sacks; Samuel B Goldfarb; Stephan A Grupp; Jill P Ginsberg
Journal:  Pediatr Blood Cancer       Date:  2008-11       Impact factor: 3.167

9.  Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children.

Authors:  I G M van der Pas-van Voskuilen; J S J Veerkamp; J E Raber-Durlacher; D Bresters; A J van Wijk; A Barasch; S McNeal; R A Th Gortzak
Journal:  Support Care Cancer       Date:  2009-01-13       Impact factor: 3.603

10.  Supernumerary Incisors in CB6F1 Mice Conditioned with Chemotherapy and Total Body Irradiation before Bone Marrow Transplantation.

Authors:  Cynthia J Doane; Karuna Patil; Emely A Hoffman; Jessica Stokes; Emmanuel Katsanis; David G Besselsen
Journal:  Comp Med       Date:  2018-09-12       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.